Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives $3.67 Consensus Target Price from Analysts

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Get Free Report) has been assigned an average recommendation of "Hold" from the five research firms that are covering the company, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $3.67.

Several brokerages have recently commented on LXRX. HC Wainwright reissued a "buy" rating and issued a $4.00 target price on shares of Lexicon Pharmaceuticals in a report on Tuesday, June 24th. Wall Street Zen started coverage on shares of Lexicon Pharmaceuticals in a research report on Monday, April 21st. They set a "sell" rating on the stock.

Institutional Trading of Lexicon Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in LXRX. Renaissance Technologies LLC acquired a new position in Lexicon Pharmaceuticals in the fourth quarter valued at approximately $38,000. Virtu Financial LLC acquired a new position in shares of Lexicon Pharmaceuticals in the 4th quarter valued at $66,000. Schonfeld Strategic Advisors LLC boosted its position in shares of Lexicon Pharmaceuticals by 301.5% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 7,558,621 shares of the biopharmaceutical company's stock worth $5,582,000 after purchasing an additional 5,676,021 shares during the last quarter. Boothbay Fund Management LLC acquired a new stake in shares of Lexicon Pharmaceuticals during the fourth quarter worth $355,000. Finally, Deutsche Bank AG lifted its stake in Lexicon Pharmaceuticals by 378.0% in the fourth quarter. Deutsche Bank AG now owns 315,659 shares of the biopharmaceutical company's stock valued at $234,000 after buying an additional 249,616 shares during the period. 74.70% of the stock is owned by institutional investors.

Lexicon Pharmaceuticals Price Performance

NASDAQ:LXRX traded up $0.06 during mid-day trading on Thursday, hitting $1.13. The company's stock had a trading volume of 5,270,290 shares, compared to its average volume of 6,863,011. The company has a current ratio of 2.22, a quick ratio of 2.22 and a debt-to-equity ratio of 0.48. The stock has a fifty day moving average of $0.73 and a 200-day moving average of $0.66. The company has a market capitalization of $408.48 million, a price-to-earnings ratio of -2.22 and a beta of 1.13. Lexicon Pharmaceuticals has a fifty-two week low of $0.28 and a fifty-two week high of $2.45.

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.03. Lexicon Pharmaceuticals had a negative return on equity of 103.16% and a negative net margin of 568.04%. The firm had revenue of $1.26 million during the quarter, compared to analyst estimates of $1.26 million. As a group, equities analysts forecast that Lexicon Pharmaceuticals will post -0.66 EPS for the current fiscal year.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.